AXQ Capital’s Ginkgo Bioworks DNA Stock Holding History

AXQ Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,997	Closed	-$99.7K	–	1062
2025 Q4	$99.7K	Buy	+11,997	New	+$129K	0.02%	652

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXQ Capital's DNA Position: Q1 2026 in Review

AXQ Capital sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 11,997 shares — an estimated $99.7K sold.

AXQ Capital first reported a position in DNA in Q4 2025 and held it in 1 quarter. The position peaked at $99.7K in Q4 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

AXQ Capital reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 11,997 Ginkgo Bioworks shares in Q1 2026, an estimated $99.7K.
AXQ Capital first reported a position in Ginkgo Bioworks in Q4 2025 and held it in 1 quarter.
AXQ Capital's Ginkgo Bioworks position peaked at $99.7K in Q4 2025.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.